Fundsmith Reduces $79M in Catalyst Pharmaceuticals, Inc. ($CPRX)
Key Points
- Fundsmith changed its Catalyst Pharmaceuticals, Inc. ($CPRX) stake by 74.9% last quarter, cutting to 844,887 shares worth $26.50 million.
- Wall Street's consensus rating on $CPRX is Hold and an average price target of $31.67.
- $CPRX last traded around $31.36.
Fundsmith reduced its position in Catalyst Pharmaceuticals, Inc. ($CPRX) by 74.9% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 844,887 shares of Catalyst Pharmaceuticals, Inc. after selling 2,518,920 shares during the quarter. Fundsmith's holdings in Catalyst Pharmaceuticals, Inc. were worth $26.50 million as of its most recent filing.
Catalyst Pharmaceuticals, Inc. ($CPRX) Stock
Catalyst Pharmaceuticals, Inc. Earnings
Analysts Set New Price Targets
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.